Synergy CHC Reports Steep Losses, Increased Cash Burn, and Informal Default Allegation Amid Highly Dilutive Financing
summarizeSummary
Synergy CHC Corp. reported a significant net loss and increased cash burn in Q1 2026, alongside highly dilutive financing activities and an informal default allegation from a senior lender, raising serious going concern issues.
check_boxKey Events
-
Significant Financial Deterioration
The company reported a net loss of $2.57 million for Q1 2026, a sharp decline from a net income of $0.88 million in Q1 2025. Revenue decreased by $2.68 million, and cash used in operating activities more than doubled to $2.04 million. Working capital shifted from a surplus to a $0.50 million deficit.
-
Highly Dilutive Equity Financing
Subsequent to quarter-end in April 2026, the company sold 3,278,030 shares under its ATM program, raising $2.67 million in gross proceeds. This represents approximately 60% of the company's current market capitalization, indicating substantial dilution for existing shareholders. An Equity Line of Credit (ELOC) was also entered into.
-
Lender Warrant Issued on Default Condition
In March 2026, the company issued 3,000,000 common stock warrants to a lender (ACP Agency, LLC) with a nominal exercise price of $0.00001 per share, exercisable upon a 'Qualified Event of Default' under the credit agreement. This represents a potential 20% dilution based on current outstanding shares.
-
Informal Default Allegation
ACP Agency, LLC has informally alleged a default under the Credit Agreement, which the company disputes. A formal declaration of default could severely impact the company's liquidity and financial stability.
auto_awesomeAnalysis
Synergy CHC Corp. reported a significant deterioration in its financial health for Q1 2026, with a substantial net loss and increased cash burn from operations. The company's working capital shifted from a surplus to a deficit, highlighting severe liquidity challenges. Despite management's assertion that recent financing activities alleviate going concern doubts, the underlying financials remain dire. The company is relying on highly dilutive equity financing, including a recent $2.67 million ATM program drawdown (representing 60% of its current market cap) and an equity line of credit. A critical $10 million equity raise is mandated by September 2026 to avoid a 2% interest rate step-up on its term loan. Furthermore, a senior lender has informally alleged a default, which the company disputes, adding significant uncertainty to its debt obligations. The issuance of 3 million warrants to a lender at a nominal exercise price, exercisable upon default, underscores the precarious financial position.
At the time of this filing, SNYR was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.28 to $4.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.